ENIGMA-TRS 2 is a global, randomized, double-blind, placebo-controlled 12-week Phase III clinical study designed to enroll at least 400 patients; topline results are expected by Q4 2026 Evenamide is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback